The presence of human papillomavirus (HPV) in unknown primary squamous cell carcinoma (UPSCC) of the head and neck at initial presentation focuses the investigation for the primary tumor on the oropharynx. The trends, frequency, and detection rate of UPSCCs have not been evaluated in the context of HPV tumor status.
U nknown primary squamous cell carcinoma (UPSCC) of the head and neck is a rare entity characterized by clinical nodal metastases without an identifiable primary tumor site. Approximately 4% of head and neck SCCs present as UPSCC. 1 Diagnostic evaluation of the primary site historically included visualization and directed biopsies of the nasopharynx, larynx, hypopharynx, and oropharynx. 2, 3 However, contemporary diagnostic evaluation has evolved to include physical examination, endoscopic and radiographic imaging, palatine and lingual tonsillectomy, and human papillomavirus (HPV) and Epstein-Barr virus detection. 1 Human papillomavirus-positive tumor status of UPSCC has emerged as an important biomarker for primary disease arising from the oropharynx. [4] [5] [6] Therefore, the presence of an HPV-positive tumor status in UPSCC permits a focused diagnostic evaluation of the oropharynx. [6] [7] [8] A disproportionate number of HPV-positive oropharyngeal SCCs compared with HPV-negative oropharyngeal SCCs initially present as UPSCC. 9 When these HPV-positive oropharyngeal primary tumors are ultimately discovered, they are commonly found in the cryptic lymphoepithelium of the palatine and lingual tonsils. 10 Although UPSCCs are strongly associated with HPV-positive tumor status, 4-9 the proportion that are HPV-positive is unknown. Several retrospective series of UPSCC arising from all head and neck sites with sample sizes ranging from 25 to 63 have estimated that 22% to 74% are related to HPV. [10] [11] [12] [13] [14] [15] [16] One series of 26 cases limited to
UPSCCs that were ultimately found to arise exclusively from the oropharynx reported the proportion of HPV-positive tumor status to be as high as 81%. 9 With the incidence of HPVrelated oropharyngeal cancer increasing in the United States and other countries, 17,18 we hypothesized that both the frequency of UPSCCs and the proportion that are HPV-positive are increasing. Identification of the primary tumor when a patient presents with a UPSCC has important clinical implications. Localization allows for more targeted therapy and potentially decreased morbidity and improved survival. [19] [20] [21] Considering that treatment outcomes depend on whether the primary tumor is detected, the diagnostic investigation remains paramount for UPSCCs. Estimates of the primary tumor detection rate for UPSCC in the literature are broad and do not account for HPV tumor status. 7, 20, 22 Transoral robotic surgery (TORS) and transoral laser microsurgery are surgical methods touted to increase the detection of primary tumors. 23 Whether UPSCC detection rates have improved in the context of these novel surgical tools is unknown. The aims of this study were to determine the changes in frequency of UPSCC evaluated over time, estimate the proportion of UPSCCs that are HPVpositive, and evaluate changes in the detection rate of primary tumors in UPSCC over time.
Methods

Patient Selection
Patients with a clinical diagnosis of UPSCC as determined by a head and neck surgical oncologist at the Johns Hopkins Positron emission tomography (PET) results were reviewed. Patients with equivocal PET scans were eligible for analysis. If a primary tumor was suspected on a PET scan but no primary site was identified after surgical evaluation, these patients were considered to have UPSCC and were therefore eligible for analysis. However, patients with a suspicious lesion on a PET scan, which was pathologically confirmed as the site of the primary tumor, were ineligible. Furthermore, if direct laryngoscopy revealed a visually suspicious lesion, which subsequently tested positive for carcinoma, these patients were also ineligible.
Statistical Analysis
Descriptive statistics were used to summarize frequencies, proportions, means, and ranges. Associations between HPV tumor status and clinical variables of interest were evaluated using Fisher exact tests for categorical variables and 2-sample t tests for continuous variables. Nonparametric tests for trend were performed across periods for the number of UPSCCs evaluated per year and the proportion of cases with primary site detection. Prevalence ratios (PRs) for primary site detection by period were estimated using log-binomial regression. The median number of surgical procedures before and after the potential use of TORS in diagnostic evaluation of UPSCC was compared using a nonparametric Wilcoxon rank sum test. A 2-sided P < .05 was considered statistically significant. Data analysis was performed using STATA statistical software, version 11.2 (StataCorp).
Results
Demographic Characteristics
The characteristics of the study population are summarized in Table 1 . In total, 84 cases of UPSCCs were eligible for analysis. The mean age of the patients was 57.3 years (range, 29-80 years). Most of the study population was male (74 of 84 [88.1%]) and had a history of ever smoking (50 of 78 [64.1%]). Human papillomavirus tumor status of metastatic cervical lymph nodes was available for 76 of 84 patients (90.5%). Of the 75 patients with HPV tumor status available, 68 (90.8%) were HPVpositive. The characteristics of patients with and without HPV tumor status were similar (P = .12).
The characteristics of HPV-positive and HPV-negative patients with UPSCCs were compared. A significantly greater proportion of HPV-positive patients with UPSCCs were male than the HPV-negative patients with UPSCCs (91.3% vs 42.9%, P = .005). The HPV-positive patients with UPSCCs were on average significantly younger than the HPV-negative patients with UPSCCs (56.1 vs 67.7 years, P = .002). The HPV-positive patients with UPSCCs were more likely to present with advanced nodal stage compared with the HPV-negative patients with UPSCCs (P = .05). A higher proportion of HPVpositive patients with UPSCCs were never smokers relative to the HPV-negative patients with UPSCCs, although this finding was not statistically significant (37.5% vs 0%, P = .09).
Trends in UPSCC Over Time
The frequency of patients presenting with a clinical diagnosis of UPSCC has significantly increased over time (P for trend = .01; Figure 1) . When considering the mean number of UPSCCs per year, an increase was observed by calendar period ( Figure 2) . The mean number of UPSCCs per year increased significantly from 3.5 cases in the earliest calendar period 
Trends in Detection
Most UPSCCs underwent diagnostic evaluation in an attempt to localize the primary site (81 of 84 [96.4%]). Therefore, analysis of detection was limited to these 81 patients. Overall, primary tumors were ultimately identified in 48 of 81 UPSCCs (59.3%). Most patients with identified primary tumors were HPV-positive (44 of 46 [95.7%]). All identified primary tumors were found in the oropharynx. Twenty-seven (56.3%) were determined to be primary tumors of the base of tongue, 20 (41.7%) of the palatine tonsils, and 1 (2.1%) that was overlapping the base of tongue and palatine tonsil. The frequency of UPSCC cases has increased significantly from 2005 to 2014 (P for trend = .01). the availability of TORS lingual tonsillectomy in 2011 affected the detection rate of primary tumors, the proportion of primary tumors identified before and after TORS was compared. A lower proportion of UPSCCs was identified in the pre-TORS period compared with the post-TORS period, although this finding was nonsignificant (53.8% vs 64.3%; PR = 1.2; P = .34; Table 2 ). Among HPV-positive UPSCCs, the detection rate over time was similar (P for trend = .14; eTable in the Supplement). Finally, the mean number of surgical procedures per patient with UPSCC before and after TORS was compared. There was no increase in the mean number of surgical procedures performed per patient after the introduction of TORS into the UPSCC diagnostic workup (1.85 vs 1.88; range, 1-4; P = .95).
Among the 48 patients with primary tumors detected, 26 (54.2%) underwent bilateral palatine tonsillectomy or bilateral lingual tonsillectomy. Of those patients, 2 (7.7%) had synchronous primary lesions. In both these cases, the tumor was HPV-positive.
Discussion
This analysis describes an increasing frequency of UPSCCs in recent calendar periods, most of which are HPV-positive. Although the increasing frequency of UPSCCs has not previously been described, it is not unexpected given the evolving epidemiologic features of head and neck cancer.
The increasing incidence of oropharyngeal squamous cell cancers in the United States and abroad is attributable to HPV infection.
17,18 Human papillomavirus-positive oropharyngeal cancers are more commonly small primary tumors with advanced nodal disease; consequently, UPSCCs are disproportionately HPV-positive. 7, 25 In light of these trends, the high proportion of HPV-positive UPSCCs in this series is consistent with the observed epidemiologic features of head and neck cancer. In this large, albeit single-institution series, 91% of contemporary UPSCCs are HPV-positive. Prior estimates varied from 22% to 81%, with most series reporting that less than 50% of cases are HPV-positive by either p16 immunohistochemical analysis or in situ hybridization. [10] [11] [12] [13] [14] [15] Similar to the epidemiology of oropharyngeal cancer, the variation may be a reflection of geographic heterogeneity 26,27 or HPV detection methods. 8 The observation that most UPSCCs are HPVpositive suggests that HPV is indeed driving the increased frequency of UPSCCs. Although the question of greater significance is whether the incidence of UPSCCs is increasing, it is challenging to determine this at a population level. The UPSCCs in the USbased population registry (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) is not specific to the head and neck but rather captures unknown primary tumors of all anatomical sites, including the abdomen and chest. Given this limitation, we investigated this question at a tertiary medical center and evaluated frequency over time but highlight the inability to provide a rate.
Consistent with the clinicodemographic distinctions between HPV-positive and HPV-negative oropharyngeal cancers, analogous clinicodemographic differences were observed between HPV-positive and HPV-negative UPSCCs.
28,29
Human papillomavirus-positive UPSCCs are more commonly found in males, younger patients, and nonsmokers compared with HPV-negative UPSCCs. This finding reinforces the notion that HPV confers a distinct clinicodemographic profile on patients with head and neck malignant neoplasms. 28, 30 This finding may reflect demographic differences in exposure to oral HPV infection.
31-35
Identification of the primary tumor for patients with UPSCC is of prognostic significance and has long been a priority. Bilateral tonsillectomies after negative direct laryngoscopy and directed biopsies have historically been recommended. 2, 3 However, lingual tonsillectomy has been advocated as a means of further increasing detection rates of unknown primary tumors. 20 Small case series with variable selection criteria have reported identification in 72% to 90% of cases. 19,20 A large series restricted to HPV-positive UPSCCs reported a detection rate of 89% using a TORS algorithm. 23 In this study, there was a nonsignificant increase in the detection rate of primary tumors before vs after TORS. Whether this can be attributed to TORS or the knowledge that HPV-positive UPSCCs are more likely to arise from the oropharynx and therefore increased diagnostic scrutiny of this site remains unknown. Given the potential morbidity of this surgical approach, including bleeding, dysphagia, and strictures, there was not a significant increase in the number of procedures per patient. New strategies, such as transcervical ultrasonography, may help guide primary tumor identification and reduce the breadth of the TORS operative field and therefore potential morbidities.
36-39
Of the cases in this study that underwent bilateral palatine or lingual tonsillectomy with the primary lesions ultimately identified, 2 of 26 (7.7%) had synchronous primary lesions. Both these synchronous primary lesions were HPVpositive. Human papillomavirus-positive synchronous primary tumors have been reported, but the pathophysiologic features remain poorly understood. [40] [41] [42] [43] Groups exploring the molecular causes of synchronous HPV-positive primary tumors hypothesize migration of HPV-infected cells throughout the Waldeyer ring or independent inoculation events by the same virus leading to field cancerization. 40 Other studies 19,23 investigating the utility of TORS for detecting primary tumors in UPSCCs have also reported synchronous primary tumors; thus, it is important to consider this possibility when evaluating patients with HPV-positive UPSCC. Whether synchronous primary tumors are more or less common in HPVpositive than HPV-negative oropharyngeal cancer is unknown. Determining this and improved estimates of the frequency of synchronous primary tumors will inform the extent of diagnostic interventions at the time of UPSCC evaluation. Although, to our knowledge, this is the largest singleinstitution series of UPSCCs in the context of HPV tumor status and describes trends over time, there are important limitations that warrant attention. As previously discussed, changes in frequency, not incidence, are described. Therefore, the frequency changes could be a reflection of institutional referral patterns and marketing, which may affect the total number of patients with head and neck cancer, rather than driven by increasing incidence of this entity. In addition, this is a retrospective singleinstitution review and therefore has the inherent biases and shortcomings of such a study, including geographic and institutional factors that may influence HPV detection. Of note, HPV detection results are not available for more than half of the earlier calendar period UPSCCs. Human papillomavirus detection results in this calendar period may be biased by physicians ordering HPV tumor detection for UPSCCs with clinical characteristics of patients with oropharyngeal cancer, which could explain why 100% of patients tested in the earliest time point were HPVpositive. Therefore, had all the UPSCCs in the earlier calendar period been appropriately tested, it would be expected that the proportion that were HPV-positive would be commensurate with later calendar periods. Finally, the distribution of calendar years per calendar periods is not equal; therefore, mean number of cases was used to evaluate questions of interest. This was dictated by the number of cases over time and calendar periods.
Conclusions
The findings of this study indicate an increasing frequency of UPSCCs and that most of these cases are HPV-positive. It is likely that the increase in HPV-related tumors is driving the increase in UPSCC. Human papillomavirus-positive UPSCCs differ from HPV-negative UPSCCs by clinicodemographic characteristics.
